Cilofexor for the Treatment of Nonalcoholic Steatohepatitis
Curr Vasc Pharmacol
.
2022;20(2):111-113.
doi: 10.2174/1570161119666211209161023.
Authors
Stergios A Polyzos
1
,
Konstantinos Xanthopoulos
2
,
Jannis Kountouras
3
Affiliations
1
First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
2
Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
Second Medical Clinic, School of Medicine, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece.
PMID:
34886776
DOI:
10.2174/1570161119666211209161023
No abstract available
Publication types
Editorial
MeSH terms
Azetidines*
Humans
Isonicotinic Acids
Non-alcoholic Fatty Liver Disease* / diagnosis
Non-alcoholic Fatty Liver Disease* / drug therapy
Substances
Azetidines
Isonicotinic Acids
cilofexor